Kite begins EU trial of CAR–T therapy – PharmaTimes
|
Kite begins EU trial of CAR–T therapy
PharmaTimes CAR-T offers a new treatment approach in that it is specifically manufactured for each individual patient. During the process, T cells are drawn from a patient's blood and reprogrammed in the laboratory to create T cells that are genetically coded to … Kite Pharma (KITE) Initiates Axicabtagene Ciloleucel CAR-T Clinical … |
